This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Coeptis Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
-60.7%
Earnings growth rate
-46.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -1,832.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Coeptis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -38 | 35 | 0 |
| 31 Mar 22 | 0 | -31 | 28 | 0 |
| 31 Dec 21 | 0 | -13 | 14 | 0 |
| 30 Sep 21 | 0 | -15 | 14 | 0 |
| 30 Jun 21 | 0 | -11 | 9 | 0 |
| 31 Mar 21 | 0 | -9 | 7 | 0 |
| 31 Dec 20 | 0 | -9 | 6 | 0 |
| 31 Dec 19 | 0 | -2 | 3 | 1 |
| 31 Dec 18 | 0 | -2 | 0 | 2 |
Quality Earnings: COEP is currently unprofitable.
Growing Profit Margin: COEP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COEP is unprofitable, and losses have increased over the past 5 years at a rate of 60.7% per year.
Accelerating Growth: Unable to compare COEP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COEP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.8%).
Return on Equity
High ROE: COEP has a negative Return on Equity (-1832.5%), as it is currently unprofitable.